Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.01 AUD | -1.96% | -6.18% | -18.54% |
May. 24 | Mayne Pharma Reiterates H2 FY24 Outlook in Wake of Change Healthcare Cyberattack | MT |
May. 10 | Mayne Pharma Group's Nextstellis Oral Contraceptive Receives Two Additional US Patents | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- With regards to fundamentals, the enterprise value to sales ratio is at 0.89 for the current period. Therefore, the company is undervalued.
- The company appears to be poorly valued given its net asset value.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-18.54% | 279M | B- | ||
+17.03% | 42.32B | B- | ||
+15.18% | 21.29B | B+ | ||
+19.33% | 15.29B | - | ||
+18.82% | 14.36B | B+ | ||
+50.83% | 12.81B | B | ||
-0.05% | 6.79B | - | - | |
-12.26% | 6.58B | B+ | ||
-8.87% | 5.73B | - | - | |
+14.28% | 5.51B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MYX Stock
- Ratings Mayne Pharma Group Limited